CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Nov 14, 2025
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2025, and provided business updates.
Read more at globenewswire.com
